A Phase 2 interventional study of diazepam nasal spray and diazepam rectal gel in Refractory Epilepsy, sponsored by Acorda Therapeutics. Terminated at 22 sites in United States. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-10-16.
Sponsored by Acorda Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Drug Resistant Epilepsy with a site in United States — 29 open to participants now, 34 under way, 2 of them phase 3. Drug Resistant Epilepsy · United States.
Among the 78 studies in Drug Resistant Epilepsy with a site in United States, this one is the 19th largest by enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2015, is one of 9 in phase 2, and was the 12th registered.
257 studies on the registry are indexed under Drug Resistant Epilepsy; 108 are open to participants now.
Browse Drug Resistant Epilepsy studies →29 of the 78 studies in Drug Resistant Epilepsy with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18–70
NeuroOne Medical Technologies Corporation · Sites in United States
Duke University · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 3–25
Mayo Clinic · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Drug Resistant Epilepsy studies recruiting now, 26 (39%) set no upper age limit and 39 (59%) stop at 75 or younger; 25 take children under 18; 6 take healthy volunteers.
This study: 12 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 17 · Phase 3 7 · Phase 4 2
First in 2001; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78 is above the median of 30 across 202 interventional studies indexed under Drug Resistant Epilepsy.
Median enrollment 27 across the 67 interventional studies, 100 across the 7 observational. Of the 34 that completed or were terminated, 14 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 78 have an industry lead sponsor. The 10 most frequent:
Acorda Therapeutics is the lead sponsor of 38 studies on the registry; none are open to participants now.
Acorda Therapeutics has 1 study filed under Drug Resistant Epilepsy — fewer than ten, so there is no comparison to draw.
13 of the studies in Drug Resistant Epilepsy with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT06443463Biohaven Therapeutics Ltd.Long-term Safety and Tolerability of BHV-7000 | 2026-12 |
| NCT06425029Dartmouth-Hitchcock Medical CenterSelf-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application | 2026-12 |
| NCT06138808Duke University5-SENSE Score Validation Study | 2027-01 |
| NCT05273970University of ArizonaElectrochemical and Electrophysiological Study | 2027-02 |
Add all 13 to your calendar (.ics) → With an account.
Among the 78 studies in Drug Resistant Epilepsy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open-label, crossover, pharmacokinetic, bio-availability study involving adolescents and adults with refractory (drug-resistant) epilepsy. Cohort 1 comprises the subjects used to determine the relative bioavailability of DZNS versus DRG (Diastat)
To determine the bioavailability of diazepam nasal spray versus diazepam rectal gel (Diastat®) under conditions of use in adolescent and adult persons with epilepsy (PWE) meeting the definition of refractory epilepsy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
Drug: diazepam nasal spray
A single rectal dose of diazepam will be administered to subjects according to the Diastat prescribing information.
Drug: diazepam rectal gel
Also known as: Diazepam
Also known as: Diastat®, AcuDial™
AUC 0-24h
Relative bioavailability based on area under time plasma concentration curve.
Time frame: 24 hours
Cmax
Relative bioavailability based on maximum observed plasma concentration.
Time frame: 24 hours
Focused Nasal Exam (Part A)
A focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Nasal irritation will be graded "none" to Grade 4 "septal perforation." Grade 1a= focal irritation, Grade 1b= superficial mucosal erosion, Grade 2= moderate mucosal erosion, Grade 3= ulceration, Grade 4= septal perforation. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted)
Time frame: pre-dose (day 1) up to 24 hours post-dose
Focused Nasal Exam (Part B)
A focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Focused Nasal Examination Part B - will show nasal mucosal symptoms that will be rated for severity will include discharge, mucosal edema, crusting, erythema, and epistaxis. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam was should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted)
Time frame: pre-dose (day 1) up to 24 hours post-dose
Smell Identification Test (SIT)
The SIT is a validated test of smell identification which scores patients into different levels of olfactory function normalized by age and gender, however it had not been validated for use in PWE. The Smell Identification Test (SIT) is a 40-item multiple-choice standardized test. The test can be self-administered and consists of four 10-page booklets with a different "scratch and sniff" strip on each page. A scratch with a pencil releases the scent from the strip, and the subject is then asked to match the scent to one of four choices on the page. An answer must be selected for each of the 40 items, even when the subject cannot detect a smell. The total score (i.e., number of correct answers, range: 0-40) can be compared against normative data collected from approximately 4000 normal individuals between ages 4 to 99 to determine the subject's percentile rank of olfactory dysfunction corrected for age and gender.
Time frame: day 1 up to day 31
Taste Change Questionnaire
Questionnaire given to safety population in Cohort 1 for reporting taste change during the study. If the subject spontaneously reports an experience of taste change associated with diazepam nasal spray dosing, it will be evaluated qualitatively by the research staff using a taste change questionnaire. The subject will be asked to describe the type, intensity, and duration of the change in taste at multiple scheduled time points after dosing. Between the 12 and 24 h time points, the questionnaire should be repeated every 4 hours as needed to follow any residual symptoms to resolution, and time of resolution should be documented.
Time frame: Up to 24 hours
This is a randomized crossover study with 78 subjects total.
| Milestone | Single Dose of Diazapam Nasal Spray (DZNS) | Single Dose of Diazapam Rectal Gel (DRG) |
|---|---|---|
| Started | 39 | 39 |
| Completed | 39 | 39 |
| Not completed | 0 | 0 |
| Milestone | Single Dose of Diazapam Nasal Spray (DZNS) | Single Dose of Diazapam Rectal Gel (DRG) |
|---|---|---|
| Started | 39 | 39 |
| Completed | 39 | 39 |
| Not completed | 0 | 0 |
| Milestone | Single Dose of Diazapam Nasal Spray (DZNS) | Single Dose of Diazapam Rectal Gel (DRG) |
|---|---|---|
| Started | 39 | 39 |
| Completed | 39 | 39 |
| Not completed | 0 | 0 |
Relative bioavailability based on area under time plasma concentration curve.
| ng*h/mL | Single Dose of Diazapam Nasal Spray (DZNS) | Single Dose of Diazapam Rectal Gel (DRG) |
|---|---|---|
| AUC 0-24h | 1357.7 ± 802.78 | 2117.9 ± 996.27 |
Relative bioavailability based on maximum observed plasma concentration.
| ng/mL | Single Dose of Diazapam Nasal Spray (DZNS) | Single Dose of Diazapam Rectal Gel (DRG) |
|---|---|---|
| Cmax | 157.0 ± 120.15 | 309.3 ± 137.95 |
A focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Nasal irritation will be graded "none" to Grade 4 "septal perforation." Grade 1a= focal irritation, Grade 1b= superficial mucosal erosion, Grade 2= moderate mucosal erosion, Grade 3= ulceration, Grade 4= septal perforation. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted)
| Participants | DZNS - At 24 Hours Post-Dose - NONE | DZNS - At 24 Hours Post-Dose - Grade 1a | DZNS - At 24 Hours Post-Dose - Grade 1b | DZNS - At 24 Hours Post-Dose - Grade 2 | DZNS - At 24 Hours Post-Dose - Grade 3 | DZNS - At 24 Hours Post-Dose - Grade 4 | DZNS - At 24 Hours Post-Dose - Missing |
|---|---|---|---|---|---|---|---|
| Nasal Irritation at Baseline - NONE | 64 | 6 | 0 | 1 | 0 | 0 | 0 |
| Grade 1a | 1 | 3 | 0 | 0 | 0 | 0 | 0 |
| Grade 1b | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
A focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Focused Nasal Examination Part B - will show nasal mucosal symptoms that will be rated for severity will include discharge, mucosal edema, crusting, erythema, and epistaxis. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam was should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted)
| Participants | DZNS - At 24 Hours Post-Dose None | DZNS - At 24 Hours Post-Dose Mild | DZNS - At 24 Hours Post-Dose Moderate | DZNS - At 24 Hours Post-Dose Severe | DZNS - At 24 Hours Post-Dose Missing |
|---|---|---|---|---|---|
| At Baseline: Mucosal Edema-None | 70 | 3 | 0 | 0 | 0 |
| Mucosal Edema - Mild | 1 | 3 | 0 | 0 | 0 |
| Mucosal Edema - Moderate | 0 | 1 | 0 | 0 | 0 |
| At Baseline: Nasal Discharge - None | 67 | 7 | 1 | 0 | 0 |
| Nasal Discharge - Mild | 1 | 1 | 0 | 0 | 0 |
| Nasal Discharge - Moderate | 0 | 1 | 0 | 0 | 0 |
| At Baseline: Mucosal Erythema - None | 67 | 6 | 0 | 0 | 0 |
| Mucosal Edrythema - Mild | 0 | 5 | 0 | 0 | 0 |
| At Baseline: Mucosal Bleeding/Epistaxis - None | 76 | 1 | 0 | 0 | 0 |
| Mucosal Bleeding/Epistaxis - Mild | 1 | 0 | 0 | 0 | 0 |
| At Baseline: Crusting of Mucosa - None | 77 | 1 | 0 | 0 | 0 |
The SIT is a validated test of smell identification which scores patients into different levels of olfactory function normalized by age and gender, however it had not been validated for use in PWE. The Smell Identification Test (SIT) is a 40-item multiple-choice standardized test. The test can be self-administered and consists of four 10-page booklets with a different "scratch and sniff" strip on each page. A scratch with a pencil releases the scent from the strip, and the subject is then asked to match the scent to one of four choices on the page. An answer must be selected for each of the 40 items, even when the subject cannot detect a smell. The total score (i.e., number of correct answers, range: 0-40) can be compared against normative data collected from approximately 4000 normal individuals between ages 4 to 99 to determine the subject's percentile rank of olfactory dysfunction corrected for age and gender.
| Participants | At Follow-Up Visit - Normosmia | At Follow-Up Visit - Mild Microsmia | At Follow-Up Visit - Moderate Microsmia | At Follow-Up Visit - Severe Microsmia | At Follow-Up Visit - Anosmia | At Follow-Up Visit - Probable Malingering | At Follow-Up Visit - Missing |
|---|---|---|---|---|---|---|---|
| At BASELINE: Normosmia | 19 | 10 | 0 | 0 | 0 | 0 | 1 |
| Mild Microsmia | 2 | 10 | 5 | 1 | 0 | 0 | 0 |
| Moderate Microsmia | 2 | 3 | 3 | 6 | 1 | 0 | 0 |
| Severe Microsmia | 0 | 1 | 1 | 4 | 1 | 0 | 0 |
| Anosmia | 0 | 0 | 0 | 2 | 3 | 0 | 1 |
| Probable Malingering | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
Questionnaire given to safety population in Cohort 1 for reporting taste change during the study. If the subject spontaneously reports an experience of taste change associated with diazepam nasal spray dosing, it will be evaluated qualitatively by the research staff using a taste change questionnaire. The subject will be asked to describe the type, intensity, and duration of the change in taste at multiple scheduled time points after dosing. Between the 12 and 24 h time points, the questionnaire should be repeated every 4 hours as needed to follow any residual symptoms to resolution, and time of resolution should be documented.
| units on a scale | Taste Change by Intensity in Cohort 1 |
|---|---|
| 5 mins Post-Dose | 6.5 ± 3.57 |
| 15 mins Post-Dose | 4.6 ± 3.09 |
| 30 mins Post Dose | 2.8 ± 2.75 |
| 1 hr Post Dose | 1.0 ± 1.45 |
| 2 hrs Post-Dose | 0.3 ± 0.48 |
| 4 hrs Post-Dose | 0.1 ± 0.36 |
| 8 hrs Post-Dose | 0.0 ± 0.0 |
| 12 hrs Post-Dose | 0.0 ± 0.0 |
| 24 hrs Post-Dose | 0.0 ± 0.0 |
Collected over 31 Days. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Diazepam Nasal Spray | 0/78 (0%) | 0/78 (0%) | 60/78 (76.9%) |
| Diazepam Rectal Gel | 0/78 (0%) | 0/78 (0%) | 20/78 (25.6%) |
| Event | Diazepam Nasal Spray | Diazepam Rectal Gel |
|---|---|---|
| Nasal DiscomfortGeneral disorders | 30/78 | 3/78 |
| DysgeusiaGeneral disorders | 25/78 | 0/78 |
| Lacrimation IncreasedGeneral disorders | 22/78 | 0/78 |
| Nasal Mucosal DisorderGeneral disorders | 10/78 | 2/78 |
| RhinorrheaGeneral disorders | 10/78 | 1/78 |
| Throat irritationGeneral disorders | 9/78 | 0/78 |
| Edema MucosalGeneral disorders | 8/78 | 1/78 |
| SomnolenceNervous system disorders | 4/78 | 5/78 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 4/78 | 0/78 |
| RhinalgiaRespiratory, thoracic and mediastinal disorders | 4/78 | 0/78 |
| Age, Categorical(Participants) | All Participants |
|---|---|
| <=18 years | 2 |
| Between 18 and 65 years | 75 |
| >=65 years | 1 |
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 41.4 ± 13.52 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 51 |
| Male | 27 |
| Ethnicity (NIH/OMB)(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 73 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 13 |
| White | 57 |
| More than one race | 0 |
| Unknown or Not Reported | 6 |
| Region of Enrollment(Participants) | All Participants |
|---|---|
| United States | 78 |
The record gives a start of Jun 2015, a primary completion of May 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2018, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diazepam